Name: Lytenava (bevacizumab-vikg) in Neovascular age-related macular degeneration: Economic burden and healthcare resource utilization
Published: 2026-09-28T12:24:10-04:00

Product information and disease description Place of product in therapy Disease description Burden of Neovascular age-related macular degeneration

Economic burden and healthcare resource utilization

4 evidence topics · 2 sources

Annual per-patient cost

“We estimated an annual all-cause cost for patients with nAMD of $24,520 per patient” (opens the source at this quote in a new tab)
“newly diagnosed patients incurred slightly lower costs ($18,943)” (opens the source at this quote in a new tab)

Outpatient and injection-related resource use

“Mean (SD) annual nAMD-related outpatient burden was 6.6 (4.8) visits overall” (opens the source at this quote in a new tab)
“Overall mean (SD) annual anti-VEGF–related outpatient visit burden was 3.9 (4.2) visits” (opens the source at this quote in a new tab)

Cost by disease activity status

“The nAMD-related outpatient visit costs were roughly 4 and roughly 7 times higher, respectively, for the active CNV group ($8,658 [SD = $11,612]) compared with the inactive CNV ($2,406 [SD = $5,510]) and inactive scar ($1,198 [SD = $3,035]) groups (P < 0.0001).” (opens the source at this quote in a new tab)

National cost estimates

“Estimates of the global cost of visual impairment due to AMD are $343 billion, including $255 billion in direct healthcare costs.” (opens the source at this quote in a new tab)